
United Therapeutics Corporation
NASDAQ:UTHR
301.42 (USD) • At close May 9, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | United Therapeutics Corporation |
Symbool | UTHR |
Munteenheid | USD |
Prijs | 301.42 |
Beurswaarde | 13,596,031,372 |
Dividendpercentage | 0% |
52-weken bereik | 260.41 - 417.82 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
Website | https://www.unither.com |
An error occurred while fetching data.
Over United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)